Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
Sign Up to like & getrecommendations! Published in 2022 at "ESMO Open"
DOI: 10.1016/j.esmoop.2022.100449
Abstract: On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, recommending a marketing authorisation for tepotinib (Tepmetko, Merck KGaA, Darmstadt, Germany), an oral, highly selective mesenchymaleepithelial transition (MET)… read more here.
Keywords: skipping mutations; met gene; cell; lung cancer ... See more keywords
Abstract CT031: Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboringMETexon 14 skipping mutations
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct031
Abstract: Introduction:MET mutations have been linked with highly progressive clinical behaviors and poor prognosis in several tumor types. Savolitinib (also known as AZD6094, HMPL-504 and volitinib) is a novel, potent, highly selective MET inhibitor and investigated… read more here.
Keywords: treatment; cancer; skipping mutations; psc ... See more keywords
Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2020.04.21
Abstract: Background Mesenchymal epithelial transition receptor (MET) alterations, including MET exon 14 skipping mutation, are oncogenic in non-small cell lung cancer (NSCLC) and may confer sensitivity to targeted therapy. Given the rarity and the diversity of… read more here.
Keywords: skipping mutations; small cell; cell lung; non small ... See more keywords